Clinical Study of SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions

Metabolic Associated Fatty Liver Disease

Interventions

BIOLOGICAL

Recombinant protein vaccine and adenovirus vector vaccine

Administer recombinant protein vaccine and adenovirus vector vaccine

All Listed Sponsors

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT05738707 - Clinical Study of SARS-CoV-2 Vaccine in Metabolism-related Fatty Liver Disease | Biotech Hunter | Biotech Hunter